NYSE American · Biotechnology · USD

Azitra, Inc. (AZTR) Stock Analysis

Azitra, Inc. (AZTR) is a Biotechnology stock listed on NYSE American and quoted in US Dollar.

AZTR

$0.18

$0.00 (0.00%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare AZTR with… →

AZTR Key Statistics

As of Sep 4, 2026

Trading

Open: $0.18
Previous Close: $0.18
Day's Range: 0.17–0.18
52-Week Range: 0.10–1.09
Volume: 330.30K
Beta: −1.07

Valuation

Market Cap: $10.88M
P/E Ratio: 8.98
EPS (ttm): 0.02

Financials (FY)

Revenue (FY): $0.00−100.00%
Net Income (FY): −$10.96M
Profit margin: 0.00%
Shares Outstanding: 60.60M
1-Year Return: −79.57%

Dividend and dates

Avg Volume: 12.37M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

AZTR Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

−81.38%−98.46%−90.67%−32.08%

2023*202420252026*

Year	Return
2026 (partial year)	−32.08%
2025	−90.67%
2024	−98.46%
2023 (partial year)	−81.38%

As of September 4, 2026.

AZTR Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$0.00	−$10.96M	—
2024	$7.50K	−$8.97M	−119566.6%
2023	$686.00K	−$11.28M	−1644.9%
2022	$284.00K	−$10.68M	−3760.7%

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$0.00	—	−$10.97M	−$10.96M	—
2024	$7.50K	—	−$10.99M	−$8.97M	−119566.6%
2023	$686.00K	—	−$7.45M	−$11.28M	−1644.9%
2022	$284.00K	—	−$9.45M	−$10.68M	−3760.7%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

AZTR Valuation vs Biotechnology Median

Median of 656 stocks

Metric	AZTR	Biotechnology median	vs median
P/E	8.98	12.57	29% below
Profit margin	0.00%	0.00%	0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

Azitra, Inc. (AZTR) is capitalised at $10.88M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 13.

The most recent close on file for AZTR is $0.18, dated September 4, 2026. The close was unchanged from the previous session. Over the past 52 weeks the price has ranged from $0.10 to $1.09. The latest close sits 80% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. Against the prior fiscal year total of $7.50K, that is a change of −100.00%. The same year closed with a net loss of $10.96M. Profit margin runs at 0%. Trailing earnings per share are 0.02.

Across the 4 fiscal years on file, revenue moves from $284.00K in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

AZTR trades at a trailing price-to-earnings ratio of 8.98. That is 28.56% below the Biotechnology median of 12.57. The medians here are taken across 656 Biotechnology companies that report the metric.

Beta against the wider market is reported at −1.07. Annualized volatility over the trailing 3 years is 187.14%. The trailing one-year price return is −79.57%. Across 3 years the annualized return works out at −92.55%.

Growth & Income

No dividend is on file for AZTR.

Across the complete calendar years on file, 2025 returned −90.67% and 2024 returned −98.46%. So far in 2026 the price is −32.08%.

Peer Comparison

Azitra, Inc. (AZTR) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Azitra, Inc.	AZTR	$10.88M	9.0
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	32.5
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	40.1

The Biotechnology industry average P/E ratio is 12.6x. Azitra, Inc. trades at a P/E of 9.0.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About Azitra, Inc.

Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and topical live biotherapeutic products to treat skin diseases in the United States. The company develops ATR-04, a genetically modified strain of S. epidermidis that is in a Phase 1/2 clinical trial for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor targeted therapy; ATR-12, a genetically modified strain of S. epidermidis, which is in a Phase 1b/2a clinical trial for treating Netherton syndrome, a skin disease; and ATR-01, a genetically modified strain of S. epidermidis that expresses an engineered recombinant human filaggrin protein, which is in the IND-enabling phase for treating ichthyosis vulgaris, a skin disease. It has a joint development agreement with Bayer for the identification and characterization of S. epidermidis strains for topical formulations. Azitra, Inc. was incorporated in 2014 and is headquartered in Branford, Connecticut.

Visit website →